• Tue. Dec 6th, 2022

Vandana Singh

  • Home
  • Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis – Aerovate Therapeutics (NASDAQ:AVTE)

Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis – Aerovate Therapeutics (NASDAQ:AVTE)

BTIG upgraded Aerovate Therapeutics Inc AVTE from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate’s benefit, Gossamer Bio Inc‘s GOSS TORREY Phase 2 results validated dry powder inhaled…

Summit Therapeutics Shares Surge After Licensing Agreement For Cancer Program – Summit Therapeutics (NASDAQ:SMMT)

Akeso Inc announced a collaboration and license agreement with Summit Therapeutics Inc SMMT to out-license its breakthrough bispecific antibody, ivonescimab (PD-1/VEGF, AK112) for development and commercialization in the U.S., Canada, Europe, and Japan.  …

EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome – BioRestorative Therapies (NASDAQ:BRTX)

BioRestorative Therapies Inc BRTX has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National…

Adidas Investigates Misconduct Allegations Against Kanye West: Report – adidas (OTC:ADDYY)

Adidas AG (OTC: ADDYY) ADDDF initiated a probe into allegations of inappropriate behavior by Kanye West after receiving an anonymous letter making several allegations. The investigation follows a report by…

Volkswagen Losing Share In Its Single Biggest Market, China – Volkswagen (OTC:VWAGY)

Volkswagen AG VWAGY VWAPY said that despite some sales gains in recent months, it expects its market share in China to be around 16% this year, down from 20% since…

Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month – Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics Inc MRTX is reportedly amid fresh takeover interest from large pharmaceutical companies ahead of updates on its drug pipeline.  For some time, the cancer-focused company has been…

Why Deere (DE) Shares Are Trading Higher – Deere (NYSE:DE)

Deere & Company DE has reported Q4 FY 22 sales of $15.54 billion, beating the consensus of $13.39 billion. The company sold out of large tractors in Q3 due to parts shortages. Deere…

OKYO Pharma Files US IND Application For Dry Eye Disease Candidate – OKYO Pharma (NASDAQ:OKYO)

OKYO Pharma Limited OKYO filed an Investigational New Drug (IND) application with the FDA for the development of OK-101 to treat dry eye disease (DED). Both nonclinical and clinical development…

HC Wainwright Creates Bullish Pitch On 4D Molecular Citing ‘Broader Systemic Potential’ – 4D Molecular Therapeutics (NASDAQ:FDMT)

HC Wainwright has initiated coverage on 4D Molecular Therapeutics Inc FDMT with a price target of $36 and a Buy rating. The analyst lists the following reasons for being bullish on the…

Why Theratechnologies (THTX) Shares Are Trading Higher Today – Theratechnologies (NASDAQ:THTX)

Cantor Fitzgerald has initiated coverage on Theratechnologies Inc THTX with an Overweight rating and a price target of $9.  Theratechnologies’ two HIV drugs, Egrifta and Trogarzo, could grow 20% a year for…

Ukraine Asserts It Does Not Take Blame For Poland Missile Attack, Crypto Exchange Gemini Suffers $485M In Outflows, FTX, Bahamas Regulator Lock Horns Over Control Of Bankruptcy Proceedings: Top Stories Thursday, Nov. 17 – BNB (BNB/USD), Bitcoin (BTC/USD)

CNBC Despite NATO Coming In Support Of Ukraine, Kyiv Asserts It Does Not Take Blame For Poland Missile Attack Ukraine’s President Volodymyr Zelenskyy said that his top military commanders…

Why Ardelyx (ARDX) Shares Are Soaring Today – Ardelyx (NASDAQ:ARDX)

The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted in favor of Ardelyx Inc’s ARDX Xphozah (tenapanor) for controlling serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.  The…

Despite NATO Coming In Support Of Ukraine, Kyiv Asserts It Does Not Take Blame For Poland Missile Attack – VanEck Russia ETF (BATS:RSX), SPDR S&P 500 (ARCA:SPY)

Ukraine’s President Volodymyr Zelenskyy said that his top military commanders had assured him that “it was not our missile and not our missile strike” that landed in Poland, killing…

Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate – Inhibrx (NASDAQ:INBX)

Inhibrx Inc INBX announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for chondrosarcoma, a rare type of cancer that usually begins in the bones. Inhibrx…

UK’s Newly Elected Prime Minister Rishi Sunak Awards $4.9B Contract To BAE Systems, Extends Support To Ukraine – BAE Systems (OTC:BAESF), BAE Systems (OTC:BAESY)

British Prime Minister Rishi Sunak extended his support for Ukraine at the G20 summit while confirming a long-planned order for warships from BAE Systems plc BAESY BAESF. “Russia’s actions put…

Several Developed Nations, Allied Groups Come Together With $10B Backing For Indonesia’s Efforts On Decarbonization – Citigroup (NYSE:C), Bank of America (NYSE:BAC)

At a G-20 meeting, a $20 billion funding plan was announced aimed at helping Indonesia, the world’s largest coal exporter, adopt renewable energy sources. Developed countries, including the U.S. and…

FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting – Humanigen (NASDAQ:HGEN), GSK (NYSE:GSK)

The FDA has issued a notice regarding the safety and effectiveness of certain naloxone hydrochloride products for nonprescription or over-the-counter (OTC) use. Naloxone is a medicine that can help reduce…

Arcutis Biotherapeutics Stock Surges After Successful Atopic Dermatitis Trial – Arcutis Biotherapeutics (NASDAQ:ARQT)

Arcutis Biotherapeutics Inc ARQT announced topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis.  The study met its primary endpoint with…

Neoleukin Pauses Development Of NL-201, Cuts 40% Of Employee Strength – Neoleukin Therapeutics (NASDAQ:NLTX)

Neoleukin Therapeutics Inc NLTX announced discontinuing the development of NL-201 for strategic reasons. Preliminary monotherapy data from the Phase 1 study of NL-201 did not demonstrate significant immunogenicity even after multiple…

RBC Capital Initiates Coverage On This MedTech Stock Citing ‘Differentiated Offering’ – Outset Medical (NASDAQ:OM)

RBC Capital Markets initiated coverage on Outset Medical Inc OM with an Outperform rating and a price target of $23. The analyst writes that Outset Medical is a medical device company that…

Mark Zuckerberg Takes Blame As Meta Lays Off 13% Of Workforce, Elon Musk’s Tesla Stock Sale May Not Sit Well With Investors, Netflix Eyes Sports Leagues: Top Stories Wednesday, Nov. 09 – Apple (NASDAQ:AAPL), Amazon.com (NASDAQ:AMZN)

Benzinga Mark Zuckerberg Takes Blame For Over-Optimism As Meta To Lay Off 13% Of Its Staff: ‘I Was Wrong’ Mark Zuckerberg, the CEO of Meta Platforms Inc META …

Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio – Avenue Therapeutics (NASDAQ:ATXI)

Avenue Therapeutics Inc ATXI acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc FBIO. Founded in December 2019, Baergic Bio focuses on developing a…

Beam Therapeutics Temporarily Retreats Clinical Plans For Second Sickle Cell Gene Therapy – Beam Therapeutics (NASDAQ:BEAM)

Last November, the FDA signed off Beam Therapeutics Inc’s BEAM Investigational New Drug (IND) application for Phase 1/2 trial for BEAM-101 gene therapy for sickle cell disease. In the most recent earnings…

What’s Going On With Veru (VERU) Stock Today – Veru (NASDAQ:VERU)

Veru Inc VERU is set to face an FDA Advisory Committee meeting on Wednesday regarding its emergency use authorization (EUA) application for the oral COVID-19 therapy sabizabulin. At first,…

GSK’s Conditionally Approved Blood Cancer Drug Fails On Progression-Free Survival Goal Over Standard Care – GSK (NYSE:GSK)

GSK plc’s GSK DREAMM-3 Phase 3 head-to-head superiority trial of Blenrep (belantamab mafodotin) for relapsed or refractory multiple myeloma (RRMM) did not meet its primary endpoint of progression-free survival (PFS). The…